Table 2.
Hazard ratios (with 95% confidence intervals) for sarcopenia- or nonalcoholic fatty liver disease (NAFLD)-related risks of all-cause and cardiovascular mortality.
| Sarcopenia | With NAFLD | |||
|---|---|---|---|---|
| All-cause mortality | ||||
| Model 1 | 1.47 (1.20–1.80) | P < 0.001 | 1.0 (0.85–1.17) | P = 0.979 |
| Model 2 | 1.46 (1.20–1.78) | P < 0.001 | 0.85 (0.72–1.10) | P = 0.052 |
| Model 3 | 1.49 (1.23–1.81) | P < 0.001 | 0.85 (0.71–1.20) | P = 0.058 |
| Model 4 | 1.47 (1.22–1.79) | P < 0.001 | 0.85 (0.72–1.01) | P = 0.071 |
| Model 5 | 1.51 (1.25–1.83) | P < 0.001 | 0.83 (0.70–0.98) | P = 0.030 |
| Model 6 | 1.45 (1.19–1.70) | P < 0.001 | 0.89 (0.75–1.05) | P = 0.196 |
| Model 7 | 1.44 (1.18–1.75) | P < 0.001 | 0.90 (0.76–1.06) | P = 0.245 |
| Cardiovascular mortality | ||||
| Model 1 | 1.73 (1.20–2.48) | P = 0.003 | 1.16 (0.86–1.57) | P = 0.314 |
| Model 2 | 1.72 (1.19–2.49) | P = 0.004 | 0.98 (0.72–1.33) | P = 0.923 |
| Model 3 | 1.87 (1.29–2.72) | P = 0.001 | 0.91 (0.67–1.24) | P = 0.586 |
| Model 4 | 1.81 (1.24–2.63) | P = 0.027 | 0.91 (0.67–1.24) | P = 0.572 |
| Model 5 | 1.92 (1.32–2.78) | P < 0.001 | 0.88 (0.65–1.21) | P = 0.457 |
| Model 6 | 1.78 (1.24–2.55) | P = 0.002 | 1.00 (0.73–1.37) | P = 0.969 |
| Model 7 | 1.78 (1.24–2.56) | P = 0.002 | 1.02 (0.75–1.39) | P = 0.875 |
To assess the hazard ratios (with 95% confidence intervals) for sarcopenia-related risks of all-cause and cardiovascular mortality, subjects without sarcopenia were served as the reference group. To assess the hazard ratios (with 95% confidence intervals) for NAFLD-related risks of all-cause and cardiovascular mortality, subjects without NAFLD were served as the reference group.
Model 1 was adjusted for age, gender, race-ethnicity, and education level.
Model 2 was adjusted for smoking and drinking status, body mass index, hypertension, and diabetes in addition to the factors included in model 1.
Model 3 was adjusted for total cholesterol, triglyceride, and HDL-cholesterol in addition to the factors included in model 2.
Model 4 was adjusted for C-reactive protein in addition to the factors included in model 3.
Model 5 was adjusted for HOMA-IR in addition to the factors included in model 3.
Model 6 was adjusted for comorbid conditions such as stoke, coronary heart disease, and chronic obstructive pulmonary disease in addition to the factors included in model 3.
For analysis of sarcopenia-related risks of all-cause and cardiovascular mortality, model 7 was adjusted for all the variables in model 6 plus NAFLD.
For analysis of NAFLD-related risks of all-cause and cardiovascular mortality, model 7 was adjusted for all the variables in model 6 plus sarcopenia.